These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37377898)

  • 1. Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy.
    Sah VR; Jespersen H; Karlsson J; Nilsson LM; Bergqvist M; Johansson I; Carneiro A; Helgadottir H; Levin M; Ullenhag G; Ståhlberg A; Olofsson Bagge R; Nilsson JA; Ny L
    Cancer Res Commun; 2023 May; 3(5):884-895. PubMed ID: 37377898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma.
    Ny L; Jespersen H; Karlsson J; Alsén S; Filges S; All-Eriksson C; Andersson B; Carneiro A; Helgadottir H; Levin M; Ljuslinder I; Olofsson Bagge R; Sah VR; Stierner U; Ståhlberg A; Ullenhag G; Nilsson LM; Nilsson JA
    Nat Commun; 2021 Aug; 12(1):5155. PubMed ID: 34453044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
    Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
    BMC Cancer; 2019 May; 19(1):415. PubMed ID: 31046743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotrap-1: an engineered soluble receptor that blocks chemokine-induced migration of metastatic cancer cells in vivo.
    Lanati S; Dunn DB; Roussigné M; Emmett MS; Carriere V; Jullien D; Budge J; Fryer J; Erard M; Cailler F; Girard JP; Bates DO
    Cancer Res; 2010 Oct; 70(20):8138-48. PubMed ID: 20736366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells.
    Takeuchi H; Fujimoto A; Tanaka M; Yamano T; Hsueh E; Hoon DS
    Clin Cancer Res; 2004 Apr; 10(7):2351-8. PubMed ID: 15073111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tobacco exposure primes the secretion of CCL21 positively associated with tertiary lymphoid structure and response to immunotherapy.
    Yin X; Wang H; Li R; Song X; Zhang T; Liang Y; Chen YZ; Yu X; Mao Q; Xia W; Chen B; Xu L; Dong G; Jiang F
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37369391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
    Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.
    Chen P; Luo S; Wen YJ; Li YH; Li J; Wang YS; Du LC; Zhang P; Tang J; Yang DB; Hu HZ; Zhao X; Wei YQ
    Cancer Sci; 2014 Nov; 105(11):1393-401. PubMed ID: 25230206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy.
    Li X; Wan Z; Liu X; Ou K; Yang L
    Med Oncol; 2022 Jan; 39(4):43. PubMed ID: 35092511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    Samlowski W; Adajar C
    BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.
    Gray JE; Chiappori A; Williams CC; Tanvetyanon T; Haura EB; Creelan BC; Kim J; Boyle TA; Pinder-Schenck M; Khalil F; Altiok S; Devane R; Noyes D; Mediavilla-Varela M; Smilee R; Hopewell EL; Kelley L; Antonia SJ
    Cancer Immunol Immunother; 2018 Dec; 67(12):1853-1862. PubMed ID: 30209589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.
    Xiong Y; Liu L; Wang J; Xi W; Xia Y; Bai Q; Qu Y; Long Q; Xu J; Guo J
    Oncotarget; 2017 Apr; 8(15):25650-25659. PubMed ID: 27783999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy.
    Thanarajasingam U; Sanz L; Diaz R; Qiao J; Sanchez-Perez L; Kottke T; Thompson J; Chester J; Vile RG
    Cancer Res; 2007 Jan; 67(1):300-8. PubMed ID: 17210711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
    Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
    Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Trial of Intratumoral Injection of
    Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
    Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
    Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
    Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
    Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
    Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
    Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.